Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
When treating adenocarinoma of the pancreas to 75 Gy in 25 fractions, what dose constraints do you use for small bowel, large bowel, and stomach?
What are your fields? Do you treat nodes electively?
Answer from: Radiation Oncologist at Academic Institution
Planning Volumes Definition Doses by Fractionation Scheme 15-Fraction 25-Fraction Microscopic Extension PTV CTV + 5mm (CTV = GTV + 1cm + CA, SMA, +/- porta hepatis, +/- splenic hilum basins) 37.5Gy/15 45Gy/25...
Sign In
or
Register
to read more
4382
Related Questions
In resected intrahepatic cholangiocarcinoma with an R0 margin <1 mm and perineural invasion, would you consider adjuvant RT in addition to capecitabine?
How would you treat a patient with cervical esophageal squamous cell carcinoma, as second primary, many years after radiation therapy with chemotherapy for Hodgkin’s disease?
In a young patient with stage IIIB, low lying rectal cancer who is s/p 8 cycles of FOLFOX, do you prefer short or long course radiation prior to surgery?
Would you offer any adjuvant therapy for a young patient with anal cancer s/p definitive chemoradiation and R0 resection with significant residual disease?
Would you recommend adjuvant chemo-RT for an upper rectal pT3N0 (2/24 nodes with positive isolated tumors cells) s/p LAR and FOLFOX?
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
Is there a role for quad-shot or similar regimen in a patient with a technically resectable, but medically inoperable colon cancer that is both bleeding and causing a partial obstruction?
Given that ESOPEC did not mandate PET staging, are the conclusions of the study still applicable for patients who are staged with PET?
Would you hold HAI/ FUDR for SBRT of a residual liver metastasis following hepatic metastasectomy?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?